Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

DANMARKS STØRSTE INVESTORSITE MED DEBAT, CHAT OG NYHEDER
Q&A med Genmab A/S, 17 Maj Kl. 15:00 Læs mere her
26/8 17:13
af Helge Larsen/PI-redaktør
This session have ended.
26/8 17:13
af Jan Van de Winkel
Thank you for a lively and energizing session. Looking forward to chat soon.
26/8 17:12
af Helge Larsen/PI-redaktør
Thank You for joining us and thank you for the many fullfilling answers to our questions. We look forward to seeing you back here on ProInvestor.com after Q3.
26/8 17:12
af Jan Van de Winkel
This is a question for Janssen who is developing Teclistamab.
26/8 17:11
af Rahul Trivedi
Also, what would be the hospitalization period for teclistamab? I believe this would play a key factor when competing with the BCMA CAR-Ts given the frequent bispecific dosing
26/8 17:11
af Helge Larsen/PI-redaktør
And now to the last question.
26/8 17:11
af Jan Van de Winkel
This requires us to continue to invest i further strengthening and broadening our product pipeline.
26/8 17:10
af Jan Van de Winkel
Genmab is very focused on creating differentiated antibody therapeutics for cancer and intends to increasingly hold on to ownership of its therapeutics..
26/8 17:09
af Bulder
Now that you can expect a solid royalty stream from Darzalex, Tepezza and Kesimpta and the fact that you have a cash position of more than DKK 12 bn, it seems that you have more than enough money for future development. Would a share buy back programme be an option?
26/8 17:08
af Jan Van de Winkel
This is a question for ADC-Therapeutics.
26/8 17:08
af Solsen
Mr Winkel What is the updated timeline for Camidanlumab and have you seen data now ?
26/8 17:07
af Jan Van de Winkel
We intend to keep focus on the potential winners and base our decisions on next steps in development on hard facts.
26/8 17:07
af Jan Van de Winkel
Genmab is a data driven company and expects to take decisions on next steps once the key data are available for the different programs..
26/8 17:06
af Sukkeralf
You have a clear strategy of focusing on the winners (like epcoritamab and PD-L1/4-1BB) - when and how will you cut down the "loosers"?
26/8 17:05
af Jan Van de Winkel
We are expanding the development program for epcoritamab very actively.
26/8 17:05
af acampi
When can we expect initiation of the next phase of epcoritamab trials?
26/8 17:04
af Jan Van de Winkel
Exciting times.
26/8 17:04
af Jan Van de Winkel
Thank you for the congratulations, and yes, there are several compounds that we would like to combine with epcoritamab. More information on the expansive development program for epco will become available in the coming months..
26/8 17:03
af acampi
Congratulations on the exciting partnership with Abbvie! Are there any compounds in the Abbvie portfolio that you are interested in combining with epcoritamab?
26/8 17:02
af Jan Van de Winkel
The regulatory decision is up to the regulators, we are very pleased with the data that are also expected to be presented at a key medical conference in the coming months.
26/8 17:01
af Akshay1976
APOLLO is like a confirmatory trial of EQUULEUS trial (3L+ MM)..but APOLLO trial also includes 2L+ MM patients..will FDA/EMA approve for 2L+ or 3L+?
26/8 17:00
af Jan Van de Winkel
We expect the first clinical data to be presented in November at a key medical conference, and cannot wait for that exciting moment.
26/8 16:59
af Solsen
Mr Winkel We look forward to se data on the PD-L1 x 4-1BB. When could that be and what year could the antibody be on the market ?
26/8 16:59
af Jan Van de Winkel
And are most excited and enthusiastic HexaBody-CD38 that is prepared for clinical production in the coming months as well.
26/8 16:58
af Jan Van de Winkel
We also have the DuoHexaBody-CD37 program in active clinical development which is progressing well..
26/8 16:58
af Jan Van de Winkel
At present Genmab is very actively exploring safety and efficacy of HexaBody DR5/DR5 and expects to have the data to base decisions for next steps within 2020..
26/8 16:57
af Sukkeralf
Have Genmab looked more into the liver toxicity in the DR5/DR5 HexaBody study - has it have something to do with the epitopes you hit or maybe the kinetics around the suicide signal or........??
26/8 16:56
af Jan Van de Winkel
The Zymeworks bispecifics have numerous unnatural mutations and are thus less likely to function as regular IgGs.
26/8 16:56
af Jan Van de Winkel
We believe strongly that the best antibody therapeutics are the ones that resemble natural antibodies most closely. Genmab's DuoBody technology creates bispecific antibodies that are identical in architechture to regular human IgGs..
26/8 16:54
af Sukkeralf
Jan you often highlight the empirical value of creating lots of BsAbs with the DuoBody platform - but what about the format. If you for instance compare with Zymeworks BsAb platform (Azymetric) which is much more flexible when it comes to formats. Depending on the targets don´t you think format matter or is it just a numbers game?
26/8 16:53
af Jan Van de Winkel
We currently believe that European regulators may want to see a control arm based study in order to progress regulatory steps in that territory.
26/8 16:53
af Jan Van de Winkel
The data of InnovaTV204 are very encouraging and form the basis of future discussions with the FDA, and could well be key to discussion with regulators in Japan..
26/8 16:52
af Sukkeralf
Which positive clinical data readouts for tisotumab vedotin are needed for filing an MAA in Europe?
26/8 16:51
af Jan Van de Winkel
Right now Camidanlumab is actively developed by ADC-Therapeutics and Genmab still owns 25% of the antibody.
26/8 16:50
af E L
Can you share anything yet on a potential increase in participation in Camidanlumab / ADCT-301? (I thought a decision was due this summer? Was it delayed by Covid or the temporary trial hold?)
26/8 16:50
af Jan Van de Winkel
Finally, our scientists are providing input to optimize robotization of corona virus screening for the population in the Netherlands, which is key because of the magnitude of the impact of the pandemic.
26/8 16:49
af Jan Van de Winkel
In addition, Genmab is providing access to its proprietary technology platforms to companies developing anti-covid19 antibody therapeutics..
26/8 16:48
af Jan Van de Winkel
One of the Genmab created antibodies, Humax-IL8 is currently tested in cancer patients that also suffer from corona virus disease by BMS..
26/8 16:48
af peter12
Are Genmab currently involved in any CV19 treatments ?
26/8 16:47
af Jan Van de Winkel
The formulation of Kesimpta has definitely been protected by Novartis and thus extent the original ofatumumab patent lifetime.
26/8 16:46
af Solsen
Mr Winkel Kesimpta is administered and dosed different from Arzerra. Does that mean a new patent protection period. And when do that expire ?
26/8 16:46
af Jan Van de Winkel
Both Genmab and BioNTech are very well capitalized and eager to progress this exciting next gen immune checkpoint program.
26/8 16:45
af Jan Van de Winkel
Right now it is too early to further comment on the expansive clinical program which is led by Genmab..
26/8 16:44
af GeorgeBest
I presume there will be an extensive developement program for PD-L1x4-1BB. Do you and especially BioNTech have enough capital resources for this, or should we expect a Big Pharma cooperation like with epcoritamab at a later stage?
26/8 16:44
af Jan Van de Winkel
We are right now creating different panels of product candidates preclinically and will start messaging time lines for clinical development of these exciting molecules once clinical candidates have been selected.
26/8 16:43
af GeorgeBest
When do you expect to move candidates from the Immatics cooperation into the clinic?
26/8 16:42
af Jan Van de Winkel
We are equally excited the DuoBody CD40x4-1BB program, which is earlier in clinical development.
26/8 16:42
af GeorgeBest
You are always very excited about PD-L1x4-1BB. Bit what about the other BioNTech duobody cooperation CD40x4-1BB. What do you expect there, and when will first data be released?
26/8 16:41
af Jan Van de Winkel
We are still in the dose escalation phase and expect to have data within this year to decide on next steps.
26/8 16:40
af GeorgeBest
Have you has further issues with toxicity in Hexabody DR5/DR5, and when can we expect to see data?
Nyeste Først- Ældste Først   Side 1/2